Condition: Advanced Solid Tumor · NSCLC (Non-small Cell Lung Cancer) · Renal Cancer · Sponsor: Nuvectis Pharma, Inc.
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
This description comes directly from the study's public registry record.
Erin Belshaw · (201) 627-8129 · ebelshaw@nuvectis.com
Shay Shemesh · (201) 614-3153 · sshemesh@nuvectis.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology Houston | Houston, Texas, United States | Recruiting |
| NEXT Oncology Dallas | Irving, Texas, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05873686